Jill DeSimone - 04 Jan 2023 Form 3 Insider Report for Oncternal Therapeutics, Inc.

Role
Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
04 Jan 2023
Net transactions value
$0
Form type
3
Filing time
05 Jan 2023, 17:01:05 UTC
Previous filing
24 May 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ONCT Stock Option 04 Jan 2023 Common Stock 10,000 $1.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest in 24 equal monthly installments with the first installment vesting on July 22, 2022, subject to the recipient's continued service.

Remarks:

Exhibit 24 - Power of Attorney